The discontinuation decision is only on the basis of commercial reasons and is not due to efficacy or safety reasons
The approved product, Mesalamine Suppositories 1000 mg, has an estimated U.S. market size of US$ 29 million
YESAFILI, a vascular endothelial growth factor (VEGF) inhibitor, is used to treat several different types of ophthalmology conditions
Expanded US manufacturing and R&D presence with investment in 10 facilities, including 7 brand new facilities
Before joining Sun Pharma, Tulla served as Senior Vice President and Chief Commercial Head – Acute Cluster at Cipla
Padmanabhan brings over two decades of extensive experience in FMCG sector
This registration authorizes Nureca Technologies to continue manufacturing and exporting asuite of medical devices to the United States
David joins HCTI with a distinguished career of over 22 years of corporate finance experience
The supply of these goods is set to commence within the first quarter of FY26
The company does not expect this development to have any material impact on the current business operations
Subscribe To Our Newsletter & Stay Updated
